The policy change effectively removes the classification of scalp cooling as a cosmetic luxury, validating its role in patient well-being. By cooling the scalp before, during, and after chemotherapy infusions, the technology constricts blood vessels to limit drug exposure to hair follicles. For patients navigating the physical toll of cancer treatment, this process offers a tangible way to maintain a sense of normalcy.
Kate Dilligan, founder and CEO of San Diego-based Cooler Heads, described the decision as a vital step toward establishing scalp cooling as a standard of care. Laurie Sandberg, the company's vice president of market access, noted that the insurer’s review process reflects a broader recognition of the comprehensive support patients require beyond primary oncological care. This coverage expansion aims to reduce the financial barriers that have historically prevented many individuals from accessing hair-preservation technology during their recovery.




Comments (0)
No comments yet. Be the first!